"Mesothelioma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Descriptor ID |
D008654
|
| MeSH Number(s) |
C04.557.470.035.510 C04.557.470.660.510
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mesothelioma".
Below are MeSH descriptors whose meaning is more specific than "Mesothelioma".
This graph shows the total number of publications written about "Mesothelioma" by people in this website by year, and whether "Mesothelioma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mesothelioma" by people in Profiles.
-
Felmly LM, Gibney BC. Commentary: Biphasic malignant mesothelioma-Survival of the fittest. J Thorac Cardiovasc Surg. 2020 04; 159(4):1596-1597.
-
Bowers JS, Nelson MH, Majchrzak K, Bailey SR, Rohrer B, Kaiser AD, Atkinson C, Gattinoni L, Paulos CM. Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight. 2017 03 09; 2(5):e90772.
-
Dominiak N, Graybill W, Gunning W, Richardson MS, Spruill LS. Peritoneal Deciduoid Mesothelioma: An Unusual Presentation Complicating an Already Challenging Diagnosis. Int J Surg Pathol. 2017 Jun; 25(4):352-356.
-
Neyens T, Lawson AB, Kirby RS, Nuyts V, Watjou K, Aregay M, Carroll R, Nawrot TS, Faes C. Disease mapping of zero-excessive mesothelioma data in Flanders. Ann Epidemiol. 2017 Jan; 27(1):59-66.e3.
-
Moolgavkar SH, Anderson EL, Chang ET, Lau EC, Turnham P, Hoel DG. A review and critique of U.S. EPA's risk assessments for asbestos. Crit Rev Toxicol. 2014 Jul; 44(6):499-522.
-
Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A. Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biol Ther. 2014 Apr; 15(4):380-8.
-
Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010 Nov 15; 70(22):9053-61.
-
Rueth NM, Murray SE, Huddleston SJ, Abbott AM, Greeno EW, Kirstein MN, Tuttle TM. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011 Jan; 18(1):174-80.
-
Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther. 2009 Dec; 8(24):2406-16.
-
Bruckner Holt CE, Farmer AD, Syn W, Shah T, Townson G. Mesothelioma - "not just in the chest". Ulster Med J. 2008 May; 77(2):133-4.